drugset / Trial / NCT00824057

Effect of Multiple Doses of AZD6280 on the Pharmacokinetics of Midazolam (CYP3A4) and Caffeine (CYP1A2)

NCT00824057

Phase 1 Completed 24 enrolled AstraZeneca
RandomizedSingle-groupQuadruple-blindBasic science

Summary

The aim of this study is to investigate the effects of taking repeated doses of AZD6280 on the blood levels of midazolam and caffeine in healthy volunteers

Timeline

Start
2009-01
Primary completion
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD6280 Small molecule Oral
Subject Caffeine Small molecule Oral
Subject Midazolam Small molecule Oral

Indications

No indication recorded.